Inventiva reports its 2022 first-half financial results and

Cash position1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 2021 Receipt of a €4 million milestone payment from...

Related Keywords

New York , United States , Daix , Bourgogne , France , Paris , France General , United Kingdom , Washington , China , Boston , Massachusetts , Russia , London , City Of , Ukraine , Netherlands , Belgium , Champagne Ardenne , Tianqing , Zhejiang , French , Sino Biopharm , Pascaline Clerc , Patricial Bank , Brunswick Group , Exchange Commission On , Chia Tai Tianqing Pharmaceutical Group , University Of Florida , Nasdaq , Market Program , Global External Affairs , French Research , Abbvie Inc , European Investment Bank , Company Phase , Drug Development Summit , Exchange Commission , Euronext , Long Island City , Euronext Paris , Chief Executive Officer , Legend Phase , At The Market Program , French State , Agricole Champagne Bourgogne , Half Year Financial Report , Non Alcoholic Fatty Liver Disease , Professor Cusi , Investigational New Drug , Greater China , Euronext Tech Leaders , Patient First Visit , Nantucket Therapeutics Conference , Tech Innovation Days , Healthcare Conference , Liver Meeting , Development Summit , Nasdaq Global Market , Global External , Roquet Montegon , Private Securities Litigation Reform Act , Universal Registration Document , Des March , Annual Report , Paris Stock Exchange Iva , Inventiva ,